PharmaFocus Today – Page 135 – media

A “dark horse” has emerged in breast cancer treatment

The birth of blockbuster drugs in the field of breast cancer is not new. After all, there is fertile soil for the birth of big drugs here. The most core factor is the extremely large patient population. Breast cancer is one of the most common cancers and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million patients were diagnosed with breast cancer. In the United States, more than 290,000 patients are expected to be diagnosed in 2023. And the proportion of important subtypes is not low. For example, HR+ breast cancer is the most common breast cancer subtype, and more than 65% of breast cancer tumors are considered to be HR+/HER2 low expression or negative. Therefore, a strong demand for drugs has been created. The growth of HR+ breast cancer cells is usually driven by estrogen receptors (ER). Endocrine therapy for ER-driven diseases is ...
- Source: drugdu
- 216
- November 19, 2024
Haoyuan Pharmaceutical’s stock price rose by more than 150%

The cold winter of CXO has lasted for three full years since the second half of 2021. From industry leaders to emerging pharmaceutical companies, everyone has felt the chill. However, since the second half of 2024, the entire industry has shown some signs of recovery. Against the backdrop of interest rate cuts in Europe and the United States, the situation in the pharmaceutical investment and financing market has reversed, orders from many listed companies have begun to grow, and the industry turning point is about to come. Haoyuan Pharmaceutical is one of the first CXO companies to feel the warmth. Since the end of August, the stock price has risen from a low of 18.49 yuan/share to a high of 46.52 yuan/share, an increase of more than 150%. Haoyuan Pharmaceutical stock price trend Image source: Oriental Fortune What is the secret of Haoyuan Pharmaceutical behind the fluctuations in stock prices? ...
- Source: drugdu
- 134
- November 19, 2024
Luye Pharmaceuticals’ “Class 1 New Antidepressant” Approved for Clinical Trial

A report released by the World Health Organization in 2017 mentioned that about 322 million people suffer from depression worldwide; according to the “2022 National Depression Blue Book”, the number of people suffering from depression in my country is as high as 95 million, but the treatment rate is only 9.5%. As social pressure increases, more and more people have mental health problems, the number of patients with depression continues to increase, and the demand for antidepressants continues to increase. According to Grand View Research, the global antidepressant market size will reach US$60 billion in 2028. At present, although there are many antidepressants available clinically, most drugs still have defects such as slow onset, low efficiency, and even sexual dysfunction and cognitive impairment. Therefore, patients still need more new and effective antidepressants. LPM682000012 is a Class 1 new drug declared by Luye Pharmaceuticals. The indication for clinical trials approved this ...
- Source: drugdu
- 157
- November 18, 2024
Johnson & Johnson’s first PFA product is approved by the FDA for marketing

Recently, Johnson & Johnson announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for its Varipulse pulsed field ablation system for the treatment of drug-refractory paroxysmal atrial fibrillation. After obtaining approval, Johnson & Johnson became the third company in the United States to have PFA technology for the treatment of AFib, joining the ranks of Medtronic and Boston Scientific, and the three-way competition in the PFA market has officially begun. It is understood that the Varipulse pulsed field ablation system consists of the Varipulse ablation catheter and the TRUPULSE generator. Among them, the VARIPULSE ablation catheter was developed based on Johnson & Johnson’s previous mapping catheter LASSO catheter, which is a continuation of the LASSO catheter technology, which further demonstrates Johnson & Johnson’s deep technical reserves in the catheter field. The Varipulse ablation catheter has 10 electrodes on the ring tip, and the ring tip ...
- Source: drugdu
- 161
- November 18, 2024
Breaking news! CEO of global orthopedic giant may be dismissed

Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has been severely warned by shareholders due to poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared: If the company’s performance cannot be improved, Deepak Nath will be dismissed, and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and advanced wound management. At present, Smith & Nephew ...
- Source: drugdu
- 154
- November 18, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
- Source: drugdu
- 180
- November 18, 2024
Chiatai Tianqing won the first place

In 2024, 207 varieties passed/are deemed to have passed the consistency evaluation in October, involving 203 companies (counted as group companies), of which 47 companies passed multiple varieties, and Zhengda Tianqing Pharmaceutical Group Co., Ltd. had the largest number of varieties passed. Chiatai Tianqing ranked first in the “number of varieties passed by the company” 1. Overall situation In October, a total of 207 varieties passed/are deemed to have passed the consistency evaluation: 151 varieties were deemed to have passed the consistency evaluation when they were launched as newly registered classified generic drugs; 59 varieties passed the evaluation with supplementary applications for generic drug consistency evaluation, an increase of 20 varieties compared to September. According to the statistics of the approval documents for marketed drugs, 12 varieties were launched in October as newly registered classified generic drugs, and the first was deemed to have passed the consistency evaluation, and 3 ...
- Source: drugdu
- 314
- November 16, 2024
“Two new Chinese medicines” approved for clinical trials

According to the CDE official website, two new traditional Chinese medicines have obtained implicit permission for clinical trials. They are the Category 2.3 new drug “Xuesaitong Soft Capsules” from China Resources Shenghuo and the Category 1.1 new drug “Jiuwei Zhengxiao” from the Institute of Clinical Basic Medicine of the China Academy of Chinese Medical Sciences. Particles”. Xuesaitong soft capsule: carotid atherosclerosis Xuesaitong soft capsule has the functions of activating blood circulation, removing blood stasis, unblocking meridians and activating meridians, and its main component is total saponins of Panax notoginseng. Currently, this drug has been approved for use in the meridian recovery period of ischemic stroke (cerebral infarction) caused by blood stasis blockage. Symptoms include hemiplegia, numbness on one side of the body, crooked mouth and tongue, and slurred speech. This time, China Resources Shenghuo’s Class 2.3 new Chinese medicine “Xuesetong Soft Capsule” has obtained another implied clinical trial license, which ...
- Source: drugdu
- 377
- November 16, 2024
Breaking news! The CEO of a global orthopedic giant may be dismissed

Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has received a severe warning from shareholders due to its poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared that if the company’s performance cannot be improved, Deepak Nath will be dismissed and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not yet “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Century-old enterprise faces crisis Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and ...
- Source: drugdu
- 238
- November 16, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its third quarter 2024 U.S. stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. The overall performance is eye-catching . In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continue to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. According to the U.S. stock financial report, BeiGene’s financial situation continues to improve, with ...
- Source: drugdu
- 279
- November 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.